Sanofi Operating Margin 2012-2026 | SNY
Current and historical operating margin for Sanofi (SNY) over the last 10 years. The current operating profit margin for Sanofi as of March 31, 2026 is 21.92%.
| Sanofi Operating Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Operating Income | Operating Margin |
| 2026-03-31 | $54.84B | $9.83B | 17.92% |
| 2025-12-31 | $52.85B | $9.83B | 18.60% |
| 2025-09-30 | $46.78B | $9.76B | 20.86% |
| 2025-06-30 | $46.96B | $9.64B | 20.53% |
| 2025-03-31 | $47.02B | $9.13B | 19.42% |
| 2024-12-31 | $47.92B | $8.22B | 17.15% |
| 2024-09-30 | $53.03B | $8.54B | 16.11% |
| 2024-06-30 | $51.29B | $7.84B | 15.29% |
| 2024-03-31 | $50.68B | $8.45B | 16.67% |
| 2023-12-31 | $50.27B | $9.59B | 19.08% |
| 2023-09-30 | $49.01B | $10.30B | 21.03% |
| 2023-06-30 | $48.42B | $11.11B | 22.95% |
| 2023-03-31 | $48.20B | $10.71B | 22.21% |
| 2022-12-31 | $47.82B | $10.72B | 22.42% |
| 2022-09-30 | $48.72B | $12.21B | 25.07% |
| 2022-03-31 | $34.76B | $8.80B | 25.31% |
| 2021-09-30 | $35.03B | $9.03B | 25.79% |
| 2021-03-31 | $43.57B | $10.31B | 23.66% |
| 2020-09-30 | $42.75B | $9.32B | 21.80% |
| 2020-03-31 | $41.19B | $7.94B | 19.28% |
| 2019-09-30 | $41.49B | $6.79B | 16.37% |
| 2019-03-31 | $41.50B | $6.71B | 16.17% |
| 2018-03-31 | $41.43B | $6.77B | 16.33% |
| 2017-12-31 | $40.92B | $7.07B | 17.27% |
| 2017-09-30 | $40.25B | $7.72B | 19.19% |
| 2017-06-30 | $39.59B | $8.01B | 20.24% |
| 2017-03-31 | $39.14B | $8.14B | 20.79% |
| 2016-12-31 | $38.41B | $7.59B | 19.77% |
| 2016-09-30 | $39.27B | $8.06B | 20.52% |
| 2016-06-30 | $39.37B | $7.47B | 18.97% |
| 2016-03-31 | $41.16B | $7.72B | 18.76% |
| 2015-09-30 | $42.97B | $7.96B | 18.53% |
| 2015-06-30 | $43.92B | $7.84B | 17.84% |
| 2014-06-30 | $44.70B | $8.29B | 18.54% |
| 2013-06-30 | $45.22B | $8.36B | 18.48% |
| 2012-06-30 | $46.75B | $9.00B | 19.24% |
| 2012-03-31 | $47.10B | $8.41B | 17.86% |
| 2011-12-31 | $47.27B | $8.89B | 18.80% |
| 2011-09-30 | $45.65B | $8.20B | 17.97% |
| 2011-06-30 | $44.35B | $8.97B | 20.23% |
| 2011-03-31 | $42.93B | $10.32B | 24.03% |
| 2010-12-31 | $41.26B | $9.22B | 22.33% |
| 2010-09-30 | $41.28B | $8.91B | 21.59% |
| 2010-06-30 | $41.42B | $8.83B | 21.33% |
| 2010-03-31 | $41.35B | $8.80B | 21.28% |
| 2009-12-31 | $40.79B | $8.81B | 21.60% |
| 2009-09-30 | $40.53B | $9.40B | 23.19% |
| 2009-06-30 | $39.73B | $8.62B | 21.69% |
| 2009-03-31 | $39.56B | $7.71B | 19.49% |
| 2008-12-31 | $40.89B | $7.99B | 19.54% |
| 2008-09-30 | $41.42B | $7.86B | 18.98% |
| 2008-06-30 | $41.43B | $8.22B | 19.84% |
| 2008-03-31 | $40.37B | $7.78B | 19.27% |
| 2007-12-31 | $39.59B | $7.93B | 20.02% |
| 2007-09-30 | $38.72B | $7.81B | 20.18% |
| 2007-06-30 | $37.43B | $7.00B | 18.70% |
| 2007-03-31 | $36.97B | $6.85B | 18.54% |
| 2006-12-31 | $35.70B | $5.85B | 16.39% |
| 2006-09-30 | $34.55B | $3.94B | 11.40% |
| 2006-06-30 | $34.49B | $5.16B | 14.96% |
| 2006-03-31 | $34.02B | $4.82B | 14.17% |
| 2005-12-31 | $33.98B | $4.48B | 13.19% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |